MedTrace Logo

Humoral Response to Tick-borne Encephalitis Vaccine in Elderly

NCT01361776 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-11-18

No results posted yet for this study

Summary

Antibody titers after tick-borne encephalitis (TBE) vaccination are less in elderly and vaccination breakthroughs are more common in this age group. This has prompted Swedish authorities to recommend an additional dose in the initial vaccination schedule (= 0+30+90 days instead of the usually recommended 0+30 days. The investigators intend to evaluate this regime.

Conditions

  • Tick-borne Encephalitis

Interventions

BIOLOGICAL

FSME-immune

0.5 ml im as scheduled in the 4 arms

Sponsors & Collaborators

  • Sormland County Council, Sweden

    lead OTHER

Principal Investigators

  • lars rombo, MD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Finland
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361776 on ClinicalTrials.gov